Wyeth is now a wholly owned subsidiary of Pfizer

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Wyeth is now a wholly owned subsidiary of Pfizer sits in the top decile of US sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count).

167 total trials none currently recruiting 139 completed early-phase tilt top decile by trial count

Wyeth is now a wholly owned subsidiary of Pfizer: 167 sponsored US clinical trials, none currently recruiting.

Wyeth is now a wholly owned subsidiary of Pfizer sponsors 167 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 139 completed. 53 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 5 trials.

Top-decile sponsor footprint

Wyeth is now a wholly owned subsidiary of Pfizer ranks in the top decile of sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

139 of 167 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

167 total, page 1 of 4

COMPLETED Phase 1

Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions

NCT01080365
COMPLETED NA

A Study To Evaluate Methods To Evaluate Back Pain

NCT01045993
COMPLETED NA

Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections

NCT01062256
COMPLETED Phase 1

Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects

NCT00952913
COMPLETED Phase 1

Study Evaluating The Coadministration of Begacestat And Donepezil

NCT00959881
COMPLETED Phase 1

Study Comparing Two Different Tablet Formulations Of Bosutinib

NCT00934674
COMPLETED Phase 1

Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses

NCT00909688
COMPLETED Phase 1

Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)

NCT00914121
COMPLETED Phase 1

Comparative Formulation Study of Vabicaserin

NCT00928551
COMPLETED Phase 1

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

NCT00894439
TERMINATED

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

NCT00847821
COMPLETED Phase 3

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

NCT00863798
COMPLETED Phase 1

Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016

NCT00838461
COMPLETED Phase 1

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

NCT00795730
COMPLETED Phase 1

Study Evaluating Single Doses of BLI-489 in Healthy Subjects

NCT00820404
COMPLETED Phase 1

Study Evaluating Single Doses of ILV-095 in Healthy Subjects

NCT00822835
TERMINATED Phase 1

Study Evaluating HTC-867 in Healthy Young and Elderly Subjects

NCT00827489
COMPLETED Phase 1

Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606

NCT00757341
COMPLETED Phase 1

Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

NCT00783341
COMPLETED Phase 4

Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

NCT00788944
COMPLETED Phase 1

Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects

NCT00721474
COMPLETED Phase 1

Study Evaluating Premarin and Bazedoxifene Potential Interaction

NCT00745173
COMPLETED Phase 1

Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016

NCT00739232
COMPLETED Phase 1

Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257

NCT00722501
COMPLETED Phase 4

Study Comparing the Efficacy of Two Ibuprofen Formulations

NCT00740857
TERMINATED Phase 1

Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease

NCT00739037
COMPLETED Phase 1

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

NCT00727064
COMPLETED Phase 1

Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women

NCT00706225
TERMINATED Phase 2

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

NCT00696787
COMPLETED Phase 2

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

NCT00669110
TERMINATED Phase 1

A Study of the Safety of PAZ-417 in Healthy Elderly Adults

NCT00663065
COMPLETED Phase 1

Study Evaluating the Safety and Tolerability of NSA-789

NCT00633048
COMPLETED Phase 1

Study GSI-136 in Healthy Young and Healthy Elderly Subjects

NCT00718731
COMPLETED Phase 2

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619
COMPLETED Phase 1

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

NCT00563524
COMPLETED Phase 2

Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

NCT00488345
COMPLETED Phase 3

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

NCT00546572
COMPLETED Phase 3

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

NCT00574548
COMPLETED Phase 1

Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

NCT00543790
COMPLETED Phase 3

Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain

NCT00631111
COMPLETED Phase 1

Study Evaluating the Safety of FXR-450 in Healthy Subjects

NCT00499629
COMPLETED Phase 1

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

NCT00543634
COMPLETED Phase 1

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

NCT00510029
COMPLETED Phase 1

Study Evaluating IMA-026 in Healthy Subjects

NCT00517348
TERMINATED Phase 1

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

NCT00521638
COMPLETED Phase 1

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

NCT00547560
COMPLETED Phase 1

Study Comparing Bioavailability of Oral Formulations of Vabicaserin

NCT00541996
TERMINATED Phase 1

Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

NCT00479622
COMPLETED Phase 1

Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects

NCT00499538
COMPLETED Phase 1

HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects

NCT00410254
Page 1 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 74
Phase 2 28
Phase 3 43
Phase 4 10

Therapeutic Areas

Healthy 5
Gastroesophageal Reflux 2
Depression 2
Skin Diseases, Bacterial 1
Peptic Ulcer Hemorrhage 1
Vaccines, Pneumococcal 1
Bacterial Pneumonia 1
Vasomotor System 1
Pneumococcal Infections 1
Arthritis, Rheumatoid 1

How the Wyeth is now a wholly owned subsidiary of Pfizer early-phase archive is shaped

167 indexed studies, none listed as recruiting (0% open); 139 completed (83%).

Phase mix: 53 late (III/IV) vs 102 early (I/II) (early-phase heavy).

Top condition: Healthy (5 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Wyeth is now a wholly owned subsidiary of Pfizer: archived-pipeline peers nationwide

Peers matched on 167 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 0%5%10%15%20% Total trials Recruiting share Wyeth is now a wholly owned subsidiary of PfizerTeva Branded Pharmaceutical Products R&DAstellas Pharma Global DevelopmentBausch Health AmericasSeattle Children's Hospital10xBio22nd Century Group23andMe3-C Institute for Social Development
Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 167 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Wyeth is now a wholly owned subsidiary of Pfizer page

167 registered trials is a research-attention snapshot, not an endorsement of Wyeth is now a wholly owned subsidiary of Pfizer or any single study.

  • None of Wyeth is now a wholly owned subsidiary of Pfizer's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Wyeth is now a wholly owned subsidiary of Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wyeth is now a wholly owned subsidiary of Pfizer pipeline card: 167 registered trials from official public datasets.Report a data error.